The potential rescheduling of cannabis under the Controlled Substances Act (CSA) has been a hotly debated topic for years. With the recent recommendation by the Department of Health and Human Services (HHS) to move cannabis from Schedule I to Schedule III, the question of how this will impact FDA oversight and regulation takes center stage. […]